Grifols | GRFS - Ebitda

Stock Price
9.07
Daily Change
0 0%
Monthly
-1.41%
Yearly
22.07%
Q1 Forecast
9.14

Grifols reported EUR482.04M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Arca Biopharma USD -25.07M 5.23M Mar/2025
aTyr Pharma USD -26.58M 26.32M Sep/2025
Bio Path USD -3.21M 631K Mar/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Capricor Therapeutics USD -24.58M 17.26M Mar/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Grifols EUR 482.04M 7.04M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Infinity Pharmaceuticals USD -10.01M 1.39M Jun/2023
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
TherapeuticsMD USD -1.64M 700K Sep/2023